Brindle Nicholas P J, Saharinen Pipsa, Alitalo Kari
Department of Cardiovascular Sciences, University of Leicester, RKCSB, PO Box 65, Leicester, LE2 7LX, UK.
Circ Res. 2006 Apr 28;98(8):1014-23. doi: 10.1161/01.RES.0000218275.54089.12.
Angiopoietin-1 (Ang1) has powerful vascular protective effects: suppressing plasma leakage, inhibiting vascular inflammation, and preventing endothelial death. Preclinical studies indicate that Ang1 may be therapeutically useful in a number of situations, including treatment of edema, endotoxemia, and transplant arteriosclerosis. However, the ligand has also been implicated in vessel remodeling, induction of angiogenesis and pulmonary hypertension, indicating that strategies to minimize any deleterious effects while optimizing vessel protection are likely to be needed. This review surveys the published data on vascular protective effects of Ang1 and highlights the therapeutic potential of this ligand, as well as possible limitations to its use. We also consider the data on Ang1 receptors and speculate on how to maximize therapeutic benefit by targeting the Tie receptors.
血管生成素-1（Ang1）具有强大的血管保护作用：抑制血浆渗漏、抑制血管炎症并防止内皮细胞死亡。临床前研究表明，Ang1在多种情况下可能具有治疗作用，包括治疗水肿、内毒素血症和移植动脉硬化。然而，该配体也与血管重塑、血管生成诱导和肺动脉高压有关，这表明可能需要采取策略在优化血管保护的同时尽量减少任何有害影响。这篇综述调查了已发表的关于Ang1血管保护作用的数据，并强调了该配体的治疗潜力以及其使用可能存在的局限性。我们还考虑了关于Ang1受体的数据，并推测如何通过靶向Tie受体来最大化治疗益处。
